April 2020 in “Online journal of complementary & alternative medicine” Some medications can help increase sexual desire and function in women.
March 2008 in “Aging health” Docetaxel is safe and works well for older people with cancer, with manageable side effects.
23 citations
,
February 2010 in “European Journal of Medicinal Chemistry”
15 citations
,
September 2008 in “Archives of Dermatological Research” Roxithromycin, an antibiotic, can increase hair growth and might be used as a treatment for hair loss.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
62 citations
,
December 1995 in “The Journal of Clinical Endocrinology & Metabolism” Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
More research is needed to understand chemotherapy-induced hair loss and its phases.
March 2026 in “International Journal of Pharmacology” Flaxseed lignans may reduce breast cancer risk in women.
4 citations
,
September 2011 in “American Journal of Clinical Dermatology” Ethinylestradiol/chlormadinone acetate may be an effective and well-tolerated treatment for skin conditions caused by excess androgens.
43 citations
,
January 2007 in “Gynecological Endocrinology” Finasteride improves acne and hair loss in women with normal testosterone.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
November 2022 in “Journal of the Endocrine Society” A transman experienced lasting virilization symptoms after stopping testosterone, which were resolved with estradiol treatment.
31 citations
,
January 2001 in “PubMed”
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
32 citations
,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
3 citations
,
January 2018 in “Journal of South Asian Federation of Obstetrics and Gynaecology” Letrozole is better for single follicle development and endometrial thickness in PCOS, with no significant difference in pregnancy rates compared to clomiphene.
November 1999 in “Reactions Weekly” 1 citations
,
January 2024 in “The Journal of Dermatology” Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
August 2006 in “JNCI Journal of the National Cancer Institute”